文献速递头颈部肿瘤放疗放疗物理与技术

头颈部离线自适应放疗项目的临床经验:剂量学获益与患者选择机会

Clinical Experience With an Offline Adaptive Radiation Therapy Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-02-17

本研究在C臂直线加速器上系统开展头颈部离线自适应放疗,用自动图像追踪系统AWARE监测解剖变化。46例患者中,自适应计划显著降低颌下腺、腮腺和口腔剂量,并降低腮腺平均剂量计算的口干症正常组织并发症概率。腮腺体积变化7%、颈部体积变化2%和淋巴结GTV体积变化29%被确定为预测自适应获益的候选触发信号。

要点

  • 头颈部离线自适应放疗在常规直线加速器上成功实施,自适应计划降低颌下腺、腮腺和口腔剂量。
  • 自适应计划使基于腮腺平均剂量计算的口干症正常组织并发症概率显著降低。
  • 腮腺ΔV=7%、颈部ΔV=2%、淋巴结GTV ΔV=29%为预测自适应获益的候选触发信号。

核心结论

  • 系统性头颈部离线自适应放疗在常规直线加速器上成功部署,降低了唾液腺关键结构和口腔的剂量。
  • 自动锥形束CT追踪提供的解剖变化信息可能有助于患者特异的自适应放疗触发。

研究设计与样本

  • 本研究为单臂临床经验报告,在C臂直线加速器上对接受放疗的头颈部癌患者系统实施离线自适应放疗。
  • 自适应在治疗期间单一时间点进行,约治疗3周时重新模拟定位。
  • 共46例患者接受自适应放疗。
  • 全程使用自动图像追踪系统AWARE通过锥形束CT扫描和可变形配准测量GTV和选定正常组织的体积变化。
  • 通过比较自适应计划剂量学与初始计划在重新模拟CT上重算的剂量学及正常组织并发症概率来确定自适应获益。

主要发现

  • 自适应计划较初始计划显著降低颌下腺剂量(均值±标准差:-219.2±291.2 cGy,P<10⁻⁵)。
  • 自适应计划较初始计划显著降低腮腺剂量(-68.2±197.7 cGy,P=.001)。
  • 自适应计划较初始计划显著降低口腔剂量(-238.7±206.7 cGy,P<10⁻⁵)。
  • 基于腮腺平均剂量计算的口干症正常组织并发症概率在自适应计划中显著降低(P=.008)。
  • 观察到GTV和正常组织在治疗期间的系统性体积缩小(ΔV)。

关键数值与推荐

  • 候选触发信号:腮腺ΔV=7%、颈部ΔV=2%、淋巴结GTV ΔV=29%。
  • 颌下腺剂量变化均值±标准差:-219.2±291.2 cGy,P<10⁻⁵。
  • 腮腺剂量变化均值±标准差:-68.2±197.7 cGy,P=.001。
  • 口腔剂量变化均值±标准差:-238.7±206.7 cGy,P<10⁻⁵。
  • 口干症正常组织并发症概率变化P=.008。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to develop a linear accelerator (LINAC)-based adaptive radiation therapy (ART) workflow for the head and neck that is informed by automated image tracking to identify major anatomic changes warranting adaptation. In this study, we report our initial clinical experience with the program and an investigation into potential trigger signals for ART. METHODS AND MATERIALS: Offline ART was systematically performed on patients receiving radiation therapy for head and neck cancer on C-arm LINACs. Adaptations were performed at a single time point during treatment with resimulation approximately 3 weeks into treatment. Throughout treatment, all patients were tracked using an automated image tracking system called the Automated Watchdog for Adaptive Radiotherapy Environment (AWARE). AWARE measures volumetric changes in gross tumor volumes (GTVs) and selected normal tissues via cone beam computed tomography scans and deformable registration. The benefit of ART was determined by comparing adaptive plan dosimetry and normal tissue complication probabilities against the initial plans recalculated on resimulation computed tomography scans. Dosimetric differences were then correlated with AWARE-measured volume changes to identify patient-specific triggers for ART. Candidate trigger variables were evaluated using receiver operator characteristic analysis. RESULTS: In total, 46 patients received ART in this study. Among these patients, we observed a significant decrease in dose to the submandibular glands (mean ± standard deviation: -219.2 ± 291.2 cGy, P < 10-5), parotids (-68.2 ± 197.7 cGy, P = .001), and oral cavity (-238.7 ± 206.7 cGy, P < 10-5) with the adaptive plan. Normal tissue complication probabilities for xerostomia computed from mean parotid doses also decreased significantly with the adaptive plans (P = .008). We also observed systematic intratreatment volume reductions (ΔV) for GTVs and normal tissues. Candidate triggers were identified that predicted significant improvement with ART, including parotid ΔV = 7%, neck ΔV = 2%, and nodal GTV ΔV = 29%. CONCLUSIONS: Systematic offline head and neck ART was successfully deployed on conventional LINACs and reduced doses to critical salivary structures and the oral cavity. Automated cone beam computed tomography tracking provided information regarding anatomic changes that may aid patient-specific triggering for ART.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Aristophanous M, Aliotta E, Lichtenwalner P, et al. Clinical Experience With an Offline Adaptive Radiation Therapy Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection. Int J Radiat Oncol Biol Phys. 2024. PMID: 38373657. doi:10.1016/j.ijrobp.2024.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。